Compare FTAI Aviation Ltd (FTAI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs BIO-TECHNE Corp — how do they compare? FTAI Aviation Ltd trades at $169.12 (market cap $17.57B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 22 Days and BIO-TECHNE Corp for 63 Days on average.
| FTAI | TECH | |
|---|---|---|
Market Cap | $17.57B | $11.36B |
Volume | 1,905,014 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $310.04 | $72.61 |
52-Week Low | $152.80 | $43.31 |
Typical Hold Time | 22 Days | 63 Days |
Enterprise Value | $20.69B | $11.39B |
Dividend Yield | 1.17% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $174.83, down 2.57% with a bearish technical signal despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51B in 2025 but missed Q2 2026 EPS estimates. Recent developments include a $500M share repurchase program and acquisition of 27 Boeing 737-700 aircraft, signaling strategic expansion in aerospace services.
FTAI presents a compelling growth story with 100% analyst buy consensus and $321.25 price target, but faces execution risks from negative operating cash flow and earnings misses. The transition to fee-based management and aerospace expansion offers upside potential, though high valuation multiples and cash flow concerns warrant caution.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
